2,089,094 Oculis Holding AG $OCS Shares Sold by Aberdeen Group plc

Aberdeen Group plc lessened its position in Oculis Holding AG (NASDAQ:OCS – Free Report) by 96.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 70,715 shares of the company’s stock after selling 2,089,094 shares during the period. Aberdeen Group plc owned approximately 0.12% of Oculis worth $660,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Braidwell LP acquired a new position in Oculis in the 2nd quarter valued at about $11,570,000. Bank of America Corp DE boosted its holdings in shares of Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after purchasing an additional 5,813 shares during the last quarter. Alps Advisors Inc. increased its stake in Oculis by 40.7% during the third quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock worth $762,000 after acquiring an additional 23,600 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Oculis in the third quarter valued at approximately $74,000. Finally, Squarepoint Ops LLC raised its position in Oculis by 326.4% in the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock valued at $854,000 after purchasing an additional 47,158 shares during the period. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Wall Street Zen raised shares of Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and set a $39.00 target price on shares of Oculis in a research note on Tuesday, November 17th. Guggenheim dropped their price objective on Oculis to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, November 4th. Finally, JPMorgan Chase & Co. cut their price objective on Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Friday, August 14th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Oculis has a consensus rating of “Moderate Buy” and an average target price of $38.57.

View Our Latest Research Report on OCS

Oculis Stock Down 5.1%

NASDAQ OCS opened at $7.06 on Friday. The stock has a fifty day moving average of $8.33 and a 200-day moving average of $17.34. Oculis Holding AG has a 52 week low of $6.78 and a 52 week high of $34.47. The stock has a market capitalization of $409.34 million, a P/E ratio of -4.13 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.41 and a current ratio of 10.41.

Oculis (NASDAQ:OCS – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.10. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.26 million. Oculis had a negative return on equity of 39.24% and a negative net margin of 8,613.92%. On average, equities research analysts forecast that Oculis Holding AG will post -1.99 EPS for the current year.

Oculis Company Profile

(Free Report)

Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.

Recommended Stories

Institutional Ownership by Quarter for Oculis (NASDAQ:OCS)

Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.